A digital strategy for scalable cell therapy manufacturing

Despite remarkable scientific progress, many therapies still struggle to make that transition successfully. Biological variability is part of the challenge, but so is the loss of process knowledge and data context as programmes move from development into manufacturing. When critical information becomes fragmented across systems, teams and documents, reproducibility, technology transfer and scale-up all become more difficult.

The consequence is not only operational inefficiency. Valuable understanding of how a process behaves, why certain decisions were made, and which parameters matter most can become disconnected precisely when it is needed most.

At Cellerator, our digital strategy is designed to address this challenge directly. We are building a unified digital foundation that enables data, process definitions and analytical context to move seamlessly from early development through GMP manufacturing. The objective is not simply to digitize existing workflows. It is to create the conditions for reliable technology transfer, stronger process understanding and more scalable manufacturing operations.

Cell therapy manufacturing will always involve biological complexity. The objective is not to eliminate variability, but to understand it, control it and learn from it.

Ultimately, digital continuity has the potential to transform inherently variable cell therapy workflows into more controlled, repeatable and scalable operations. Not because digital tools replace scientific expertise, but because they help ensure that valuable process knowledge is retained, shared and continuously improved as therapies move from development to manufacturing and, ultimately, to patients.

Designing for translation

A core principle underpins our approach: data generated during process development should remain directly usable throughout the lifecycle of a therapy.

Too often, critical manufacturing components are introduced late in the development journey, requiring scientific information to be reformatted, reinterpreted or manually reconstructed. Every translation step introduces risk. And important relationships between process parameters, analytical results and manufacturing outcomes can become fragmented, reducing the ability to learn from data as programmes mature.

Instead, we capture experimental and operational data in structured formats from the outset, ensuring that process definitions, critical parameters and historical outcomes retain their context as development progresses. Rather than adapting processes to manufacturing systems later, we design the digital framework to support translation from day one.

The goal is simple: information generated during development should flow naturally into manufacturing, quality and operational processes without losing the context that gives it meaning.

Creating the foundation for predictive manufacturing

One of the most significant opportunities created by a unified data foundation is the ability to preserve context across the entire development and manufacturing lifecycle.

When data maintains a common structure from process development through GMP production, relationships between critical process parameters (CPPs) and critical quality attributes (CQAs) can be retained and analysed over time. This enables a deeper understanding of process behaviour and creates the foundation for more advanced modelling approaches.

Artificial intelligence and machine learning are becoming increasingly important topics across the life sciences industry. However, meaningful predictive capabilities depend first on having structured, traceable and high-quality data. Without that foundation, even the most sophisticated analytical tools have limited value.

For us, the digital thread is therefore not primarily an AI initiative. It is the infrastructure that makes future predictive capabilities possible.

By preserving process knowledge, maintaining data integrity and ensuring continuity across systems, we can create the conditions for hybrid mechanistic and data-driven models that help identify sources of variability, interpret process behaviour and improve manufacturing outcomes.

Building a digital thread

At the centre of this strategy is a continuous digital thread connecting process development, manufacturing, quality control and enterprise operations.

This digital thread is enabled through an integrated platform that combines Electronic Lab Notebooks (ELN), Laboratory Information Management Systems (LIMS), Electronic Batch Record Systems (EBR), Scientific Data Management Systems (SDMS), Quality Management Systems (QMS) and Enterprise Resource Planning (ERP). Together, these systems operate on a harmonized master data model, creating a common framework for materials, methods, parameters, analytical results and operational data.

The value of this approach becomes particularly clear during technology transfer, one of the most challenging stages of cell therapy manufacturing.

Traditional transfer packages often capture procedures and instructions but rarely preserve the full context behind how a process performs in practice. Parameter relationships, analytical results, historical performance and development insights frequently become separated as information moves between functions.

Our ambition is to move beyond document-centric technology transfer towards digital process transfer. Process knowledge should travel with the process itself. Manufacturing teams should inherit not only instructions and specifications, but also the context and understanding behind them. In that way, technology transfer becomes more than a handover of documents. It becomes a transfer of knowledge.

The same principle applies within GMP manufacturing. Structured digital execution reduces manual transcription, improves traceability and enables electronic batch records to be generated as part of execution rather than assembled afterwards. Quality data becomes directly linked to process execution, creating complete batch genealogy and automated audit trails that support both operational efficiency and regulatory readiness.

Connecting scientific and operational performance

The value of a unified digital foundation extends beyond manufacturing execution.

By integrating execution data with ERP systems, organisations gain real-time visibility into material consumption, labour utilisation, inventory levels and process costs.

This enables more informed decisions around scale-up, capacity planning, forecasting and operational efficiency. Process performance, operational performance and financial performance become part of the same decision-making framework. For emerging cell therapy programmes, where resources are limited and timelines are critical, this visibility becomes increasingly important as manufacturing activities scale and complexity grows.

At the same time, a connected data environment helps reduce duplication, eliminate unnecessary reconciliation activities and establish a single source of truth across development, manufacturing and quality functions.

By establishing a unified data platform and an end-to-end digital thread, we aim to preserve process knowledge throughout the lifecycle of a therapy, improve technology transfer, strengthen manufacturing consistency and create an analysis-ready foundation for future innovation.